Compare Moderna, Inc. (MRNA) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Raymond James Financial, Inc. — how do they compare? Moderna, Inc. trades at $59.73 (market cap $23.60B), while Raymond James Financial, Inc. trades at $168.25 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | RJF | |
|---|---|---|
Market Cap | $23.60B | $32.80B |
Sector | Health | Financials |
52-Week High | $81.80 | $176.43 |
52-Week Low | $22.36 | $140.89 |
Enterprise Value | $19.70B | — |
Dividend Yield | — | 1.28% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
